Intraoperative MRI (iMRI) is used in glioma surgery mainly to determine the extent of resection, allowing surgeons to immediately continue resection in case of residual tumor tissue. The aim of this study is to report on the influence of the use of iMRI on the extent of resection and survival of patients with glioblastoma multiforme (GBM).
Introduction
Cytoreductive surgery has been marking the first step in the treatment of glial tumors for decades (1). Even though malignant, i.e., high-grade gliomas can usually be distinguished intraoperatively from healthy brain parenchyma more easily than low-grade gliomas in the majority of cases, the intraoperative differentiation of tumor tissue from normal tissue remains difficult quite frequently. Even in dedicated neurosurgical centers, these difficulties account for unintentionally remaining tumor tissue being identified on early postoperative MRI scans in a considerable number of patients (2).
It is a well-recognized, distinct feature of gliomas to diffusely infiltrate brain tissue. From a biological point of view, complete resections therefore cannot be achieved. However, several well-conceived and well-conducted studies have recently indicated that the extent of resection as determined by the removal of contrast-enhancing tissue on MRI is one of the most important prognostic Technology in Cancer Research & Treatment, Volume 9, Number 4, August 2010 factors for progression-free and overall survival in patients with high-grade gliomas (3, 4) .
To provide the neurosurgeon with information about the extent of resection intraoperatively, intraoperative magnetic resonance imaging (iMRI) has evolved as an elegant method, offering additional integration of functional anatomical data and allowing for the intraoperative update of neuronavigation (5) (6) (7) (8) (9) . Numerous reports deal with the implementation of iMRI into the neurosurgical routine, indicating that iMRI is safe and reliable in the visualization of residual tumor tissue intraoperatively (10) (11) (12) (13) . We previously reported that the use of iMRI affected the course of surgery by means of continued resection after intraoperative scanning in approximately 25 % of patients with high-grade gliomas (7). Yet to date, a clear proof of the usefulness of iMRI in terms of improved patient survival is missing.
With this analysis, we aim to assess whether the use of iMRI improves the extent of resection in patients with glioblastoma multiforme (GBM) and whether this influences the outcome of our patients.
Material and Methods
We retrospectively analyzed our prospectively collected database of patients with glial tumors treated at our institution. In July 2004, an intraoperative ultra-low field strength MRI (PoleStar N-20, Odin Medical Technologies, Yokneam, Israel/Medtronic, Louisville, CO) was installed in one of our operating rooms (14). The PoleStar is a compact mobile iMRI device, specifically designed for application in cranial neurosurgery, and it is entirely operated by the neurosurgeon and . The gap between the magnets, in between which the patient's head is positioned, is 27 cm wide, and the ellipsoid field of view depicted by the PoleStar measures 20 cm × 10 cm. The low magnetic field strength of 0.15 Tesla allows the use of regular surgical instruments and microscopes, but for safety reasons, all anesthesia-related devices are positioned outside the 5-Gauss line, which is marked on the OR-floor. Figure 1 illustrates the intraoperative surgical set-up.
All patients with primary GBM, as confirmed by independent histopathological analysis (according to the WHO classification of brain tumors), who underwent intended radiologically complete tumor resection between July 2004 and December 2005 with a preoperative KPS ≥ 70 were included in this analysis. A panel of experienced neurosurgeons determined the goal of radiologically complete tumor resection, i.e., the removal of all contrast enhancing tumor tissue, preoperatively according to the site of the tumor. We did not intend to achieve a complete tumor resection in patients with eloquently located tumors, i.e., tumors infiltrating the basal ganglia or the corpus callosum -in these, we intended to achieve subtotal or partial resections. Patients with recurrent tumors, or patients who were scheduled to undergo subtotal or partial resection or only biopsy of their tumors were not included in this analysis.
All operative procedures were performed as standard microneurosurgical procedures. We had no defined protocol regarding patient selection for iMRI, thus it was at the attending neurosurgeon's discretion whether to use iMRI or not. All patients had given their written informed consent prior to surgery; patients chosen for iMRI-guided tumor resection had additionally consented to iMRI.
Within 72 hrs postoperatively (24-48 hrs in the vast majority), all patients routinely underwent 1.5 Tesla (T) MRI-imaging Right: Tumor resection is performed as a microsurgical procedure while the magnet is placed underneath the patient's head. The magnet is elevated for intraoperative scanning.
to determine the extent of tumor resection and to rule out complications. Subsequently, all patients were subjected to radiotherapy according to standard protocols with an approximate dose of 60 Gray, optionally with concomitant and adjuvant temozolomide in most patients. The administration of chemotherapy was conducted according to clinical protocols and subject to patient preference (16, 17) . Subsequently, all patients were routinely followed with clinical examinations and MRI follow-up on a 3-monthly basis. In the event of tumor recurrence, patients were offered salvage chemotherapy protocols and re-resection of their tumors, if possible.
Experienced neuroradiologists, blinded for the treatment modality of iMRI-guided or conventional microneurosurgical resection, respectively, evaluated the extent of resection on early postoperative MRI scans. The extent of resection was classified as "complete" when no residual contrast-enhancing tumor was seen on T1-weighted imaging, and "incomplete" if residual nodular contrast enhancing tissue was detected. Hyperintense signals already visible on non-infused T1-weighted scans were regarded as surgically induced, not indicating residual tumor tissue.
For statistical analyses, commercially available software was used (SPSS 17.0, SPSS Inc., Chicago, IL). The influence of iMRI on the extent of resection and differences in postoperative treatment were evaluated with Fisher's exact test. Kaplan-Meier-estimates and Log rank tests were used to evaluate factors influencing survival (extent of resection, patient age, patient sex, use of iMRI, adjuvant chemotherapy). Multivariate analyses were performed using a Cox regression model (backward stepwise). P-values < 0.05 were considered statistically significant.
Results
A total of 43 consecutive patients with a preoperative KPS ≥ 70 underwent intended complete resection of a suspected contrast enhancing, primary high-grade glioma in the study period. Histopathological examinations later determined WHO-grade IV gliomas in all cases (glioblastoma N = 41; gliosarcoma N = 2). Of these, 10 patients (23.3%) were assigned to undergo tumor resection with the use of iMRI (iMRI group), 33 patients (76.7%) underwent conventional tumor resection (conventional group). Figure 2 gives an example of intraoperatively acquired images before and after tumor resection. After surgery and discharge from our unit, two patients who had been operated without the use of iMRI were lost to follow-up, so they were excluded from further analysis.
Our series consisted of 25 male (61%) and 16 female (39%) patients with a median age of 60.0 years (range: 17-84 years, mean age 59.2 years). The distribution of age between the two treatment groups (iMRI vs. conventional group) was balanced with a median age of 60 years in the iMRI group, and 60.5 years in the conventional group, respectively. The gender distribution was similarly balanced with respective percentages of male patients of 60% (iMRI group) and 61% (conventional group).
Postoperatively, the majority of patients received radiation therapy with concomitant temozolomide (N = 34); of these, 15 continued to receive temozolomide chemotherapy in an adjuvant fashion after radiation therapy similarly to the protocol later described by Stupp et al., (16) . Only 7 patients, 3 of whom belonged to the iMRI group, received radiotherapy alone, so there were slightly more patients who received radiation therapy alone in the iMRI group (30%) than in the conventional group (13%), although this difference was not statistically significant (P = 0.33). When looking at patient age as a prognostic factor influencing survival, there were no statistically significant differences in median survival between patients younger or older than 60 years in our series, although younger patients tended to have better outcome. Kaplan-Meier analyses rendered a median survival of 72.4 weeks for patients < 60 years and 67.9 weeks for patients ≥60 years, respectively (95%CI: 66.8-121.1 and 55.4 -88.5 weeks; P = 0.23).
After performing a multivariate analysis, only complete tumor resection (P < 0.001) and the administration of temozolomide (P = 0.02) were independently associated with prolonged survival, while the mere use of iMRI was not.
Discussion
Even though not leading to a definitive cure of the disease, surgical tumor resection to a maximum safe extent has been Postoperative 1.5 T MRI confirmed complete tumor resection in a total of 29 patients (70.1 %). When comparing the extent of resection between the two treatment groups, we found a significantly higher rate of radiologically complete tumor resections in the iMRI group compared with the conventional group: in the iMRI group, we achieved a 100 % rate of complete resections compared to 61 % in the conventional group (P = 0.02; Table I ).
As of Dec 1, 2009, 2 patients were still alive after diagnosis while 39 had died. Mean follow up was 82.2 weeks. Median overall survival as rendered by Kaplan-Meier analysis was 70.7 weeks (range: 5.0-249.6 weeks; 95% confidence interval [CI]: 66.7-98.6 weeks). For patients with complete tumor resections, median survival was 73.9 weeks (95%-CI: 60.1-87.6 weeks). For patients with incomplete tumor resections, survival was lower with a median of 46.0 weeks. This difference was statistically highly significant (P < 0.001; Figure 3 ). Moreover, there were no significant differences in age between patients who had undergone complete or incomplete tumor resection (Table II) , indicating no treatment bias with respect to age.
After stratification between treatment groups, median survival for patients undergoing iMRI-guided resection was 88.1 weeks (95% CI: 70.7 -136.2 weeks) whereas median survival for patients undergoing tumor resection without iMRI was markedly lower with 67.9 weeks (95% CI: 58.4 -92.4 weeks). However, this difference did not quite reach statistical significance (P = 0.07; Figure 4) . Similarly, the administration of any form of temozolomide (concomitantly or concomitantly and adjuvantly to postoperative radiation therapy) was associated with prolonged survival compared to radiation therapy 22). Several systems differing in setup, field strength, and neurosurgical workflow have been employed, and they all have shown to be safe and reliable in neurosurgery as indicated by numerous reports (23) (24) (25) (26) (27) (28) . In addition to intraoperative tumor visualization, the use of iMRI further allows the incorporation of (functional) anatomical data (29-31). A major advantage of iMRI is the possibility to update the anatomical information used for neuro-navigation in an almost online fashion, thereby eliminating the problem of brain-shift in conventional neuro-navigation (7). More extensive resections with less residual tumor volume have been reported after an intraoperative update of neuro-navigation when performing iMRI-guided tumor resections (32). The use of iMRI-guidance is mainly indicated in, but not limited to, brain tumor resection (33) (34) (35) .
Several groups have reported that iMRI has influenced the course of surgery and thus led to an increased rate of complete tumor resections. In high-grade gliomas, resection was resumed after iMRI revealed residual enhancing tumor tissue in up to 70% of the cases (8, 31, (36) (37) (38) . When previously analyzing a series of 42 patients with contrast enhancing high-grade gliomas, we found residual enhancing tumor in 8 out of 30 patients (27.6%) with intended complete resection at a point, when the surgeon believed to have achieved complete resection; iMRI finally helped to achieve a complete resection in all 30 patients (7). Although arguably intraoperative imaging sequences might have been conducted liberally in some cases, simply because the surgeon knew that iMRI was available, it becomes evident that the implementation of iMRI greatly influenced the course of surgery in a large number of patients. Studies regarding the extent of resection in patients undergoing iMRI-guided surgery compared to a control group are lacking.
the first step in the multimodality treatment of glioma patients.
Recently, evidence has been increasing that progression-free and overall survival are positively correlated with the extent of resection, emphasizing the importance of surgical intervention (18) (19) (20) .
Intraoperatively, the identification of tumor margins can be difficult. Due to the functional relevance of brain tissue, resections with a safety margin cannot be performed safely and thus must not be undertaken. To overcome this problem of intraoperative tumor visualization, several methods have been developed and assessed.
High-grade tumor tissue can be visualized by means of administration of fluorescent porphyrins and their precursors, to be ingested by the patient several hours before surgery -using a special microscope, the tumor can later be distinguished from healthy brain parenchyma under fluorescent light (21). A controlled randomized trial showed that the extent of resection of glioblastomas was enhanced by application of this method, resulting in an improved overall survival (3, 19) .
Another method to detect residual tumor tissue was the implementation of iMRI into the neurosurgical routine (10, There was a trend in favor of iMRI, suggesting that the difference might reach statistical significance in a larger cohort of patients.
Limitations of our study undoubtedly are the small sample size for patients undergoing iMRI-guided resection and the fact that patients were not truly randomized to undergo either method of tumor resection. We also acknowledge the fact that patient selection for iMRI might have been biased by personal preferences of the surgeons; yet, our data show that patient age and sex were well balanced between the two groups. To rule out any potential biases, a prospective randomized trial would certainly be necessary. Until today, however, our study represents the first report on improved resection in a consecutive series of patients undergoing surgery for GBM with iMRI-guidance compared to a control group treated in the same time frame, albeit being a retrospective and small one.
Conclusion
The implementation of intraoperative MRI as a technology has had an enormous impact in the neurosurgical treatment of malignant brain tumors. Both, the extent of resection and the administration of temozolomide in addition to radiation therapy significantly influence patient outcome (16, 19) . Our study for the first time shows that iMRI is an appropriate tool to increase the extent of resection in patients with GBM compared to a control group of patients; however, the use of iMRI itself did not reach statistical significance as a prognostic factor. Prospective, randomized trials are now necessary in order to eliminate any potential biases. Future analyses of larger series might prove the true benefit of iMRI in brain tumor surgery.
Only few studies have thus far addressed the effect of iMRI on patient outcome. In a series of patients undergoing iMRI-guided resection, we recently reported that survival of patients with complete resections was longer than that of patients with incomplete resections, adding to the evidence already available that the extent of resection is a prognostic factor for patients with malignant gliomas (39). When performing a matched-group analysis for a series of 32 WHO grade IV glioma patients, Hirschberg et al., found a trend in favor of iMRI, but no significant differences in overall survival between the groups (40). These results were not surprising, since not iMRI alone, but the extent of resection, which in turn can obviously be influenced by iMRI, represents the prognostic factor. Therefore, survival is expected to be comparable in two balanced groups with similar rates of complete tumor resection.
In this series of patients undergoing intended complete tumor resection, the extent of resection was the strongest variable affecting survival of patients with GBM. The rate of complete resections was significantly higher in the iMRI group than in the conventional group, indicating a benefit of iMRI use. Complete tumor resection could be achieved in all patients in the iMRI group, and we could show that, again, complete tumor resection was a prognostic factor in glioblastoma, increasing the median survival by more than 7 months. We did not observe a statistically significant difference in overall survival between the iMRI and conventional group, despite an increased rate of complete tumor resections. This can most likely be explained by the small sample size. Another reason may be the fact that there was a slightly larger proportion of patients receiving only radiotherapy in the iMRI group than in the conventional group. 
Disclosure
Thomas Gasser, M.D., Ph.D., serves as clinical consultant to Medtronic, but there has been no financial support of this study by the company. All other authors declare that they have no conflicts of interest.
